OnKure Therapeutics, Inc. Class A Common Stock (OKUR)

• Market cap: $33.6M
• 1 day: 0.40%
• 5 days: -4.21%
• 1 month: -41.31%
• 3 months: -57.56%
• 6 months: -84.65%
• Year to date: -70.66%
• 1 year: 46.20%
• 5 years: -82.00%
• 10 years: -82.00%
• Sector: Healthcare
• Industry: Biotechnology

About: OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Employees: 46

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

103% more capital invested

Capital invested by funds: $49M [Q3] → $99.2M (+$50.2M) [Q4]

7.33% more ownership

Funds ownership: 86.28% [Q3] → 93.6% (+7.33%) [Q4]

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 51 [Q3] → 51 (+0) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

70% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 23

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 1,100% upside
• Avg. target: $32 1,180% upside
• High target: $34 1,260% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 172 met price target	1,260% upside $34	Buy Maintained	18 Mar 2025
Oppenheimer Matt Biegler 0% 1-year accuracy 0 / 2 met price target	1,100% upside $30	Outperform Maintained	11 Mar 2025